Provided by Tiger Fintech (Singapore) Pte. Ltd.

Taysha Gene Therapies, Inc.

2.80
-0.0400-1.41%
Post-market: 2.890.0900+3.21%19:54 EDT
Volume:1.89M
Turnover:5.32M
Market Cap:733.60M
PE:-8.38
High:2.93
Open:2.92
Low:2.77
Close:2.84
Loading ...

Taysha Gene Therapies Is Maintained at Buy by Chardan Capital

Dow Jones
·
27 Feb

Positive Outlook on Taysha Gene Therapies: Promising Developments and Financial Stability

TIPRANKS
·
27 Feb

Taysha Gene Therapies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Feb

Taysha Gene Therapies, Inc. (TSHA) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
26 Feb

Taysha Gene Therapies Q4 EPS $(0.07) Beats $(0.08) Estimate, Sales $2.02M Miss $2.31M Estimate

Benzinga
·
26 Feb

Press Release: Taysha Gene Therapies Reports Full-Year 2024 Financial Results and Provides Corporate Update

Dow Jones
·
26 Feb

Taysha Gene Therapies Inc expected to post a loss of 8 cents a share - Earnings Preview

Reuters
·
24 Feb

Taysha Gene Therapies to Release Full-Year 2024 Financial Results and Host Conference Call and Webcast on February 26

GlobeNewswire
·
19 Feb

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
07 Feb

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
07 Feb

Taysha Gene Therapies Price Target Maintained With a $6.00/Share by Needham

Dow Jones
·
06 Jan

Taysha Gene Therapies: Promising Developments and Strategic Investment Opportunity

TIPRANKS
·
06 Jan

Acelyrin Leads The Charge With 2 Other US Penny Stocks

Simply Wall St.
·
06 Jan

Taysha Gene Therapies announces inducement grant under Nasdaq listing rule

TIPRANKS
·
03 Jan

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
03 Jan

Press Release: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Dow Jones
·
03 Jan

Taysha Gene Therapies files $300M mixed securities shelf

TIPRANKS
·
14 Dec 2024